On October 25, 2021 Silenseed, a Tel Aviv RNAi company, reported that it raised $7.8 million from the Guangzhou Sino-Israel Bio-Industry Investment Fund to start a China JV (Press release, Silenseed, OCT 25, 2021, View Source [SID1234593957]). Silenseed-China will own the rights to develop, market and sell Silenseed’s RNAi products in China. The Israeli company will use the capital to conduct a Phase III trial of its lead candidate, which targets the KRAS oncogene to treat pancreatic cancer. Silenseed’s novel drug delivery platform enables the insertion of RNAi therapeutics directly into solid tumors. GIBF will own a 49% stake in the Silenseed Chinese subsidiary.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!